ArticleNeurology and therapy2026
Patient Preferences Toward CGRP-Targeting Preventive Migraine Treatments in Japan: Discrete Choice Experiment.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo date, no Japanese study on migraine has evaluated how treatment characteristics affect patient preferences between novel gepants and subcutaneous or novel intravenous calcitonin gene-related peptide (CGRP) monoclonal antibodies. A survey using a discrete choice experiment (DCE) was therefore conducted to identify treatment preferences for CGRP-targeting preventive therapies in this population.
methodsPreventive-treatment attributes and levels were identified via a literature review, pivotal clinical trials, and international regulatory documents. These levels included those of CGRP-targeting therapies under development in Japan. A five-patient focus group was conducted to confirm patient understanding of the attribute descriptions and identify other potential attributes. Results from the focus group interview and from clinician input informed a questionnaire, which was revised following a pilot survey (N = 39), then an online main survey was conducted in May-June 2025 with eligible patients. A DCE was used to quantify patient preferences, and a conditional logit model was used to calculate preference weights and 95% confidence intervals.
resultsThe questionnaire included six attributes: 50% reduction rate of migraine frequency, speed of effect, effect on impairment of daily activities, frequency of side effects, frequency of injection-site reactions, and administration method. The main survey included 324 patients (79% women; mean age 47 years) who experienced an average of eight migraine days per month. The survey revealed that effect on impairment of daily activities was the most important attribute, followed by administration method, and frequency of injection-site reactions. Regarding attribute levels, oral CGRP-targeting formulations were preferred over injectables within the specific attribute combinations used in this DCE.
conclusionsThese findings suggest that, under the design conditions used in this DCE, participants with migraine in Japan favored non-invasive oral CGRP-targeting treatments that effectively reduce impairment of daily activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.